980 results
Thumbnail

D3.180 - Good patient adherence to sublingual immunotherapy for allergic rhinitis can be achieved, when ENT-physicians collaborate with pharmacies in a straightforward adherence programme

Thumbnail

D3.182 - Health Economic Evaluation of 5-Grass Pollen Sublingual ImmunotherapyTablets for Grass Pollen-Induced Allergic Rhinitis in Finland, Norway and Sweden

Thumbnail

D3.183 - Reduction in Healthcare Resource Utilization in patients treated with 300 IR liquid SLIT: Real-World Evidence from Spain and Italy

Thumbnail

D3.184 - Treatment with the 300 IR house dust mite sublingual tablet is safe and well tolerated in adults and adolescents in a real-world data setting – results of a non-interventional post authorization safety study

Thumbnail

D3.185 - The 300 IR house dust mite sublingual tablet is effective and well tolerated in patients with allergic rhinoconjunctivitis and concomitant allergic asthma in a real-world data setting

Thumbnail

D3.186 - A new allergenic protein in holm oak (Quercus ilex) pollen: Glutathione-S-transferase

Thumbnail

D3.187 - Adverse reactions to sublingual immunotherapy with carbamylated allergoids of different sources in clinical studies

Thumbnail

D3.188 - Comparison of Completion Rates and Factors Influencing Discontinuation in Paediatric Allergen Immunotherapy: A Five-Year Single-Center Experience

Thumbnail

D3.189 - Adverse reactions to subcutaneous immunotherapy for mite in children and adolescents in a tertiary care center

Thumbnail

D3.19 - Evaluation of allergens in Atopic Dermatitis in children between 6 months and 18years

Thumbnail

D3.190 - Follow up cases of subcutaneous allergen Immunotherapy in respiratory allergic diseases continuing for 10-30years “A Real life experience of 14 cases”

Thumbnail

D3.191 - Case report: Acute systemic reactions to sublingual immunotherapy for tree pollen

Thumbnail

D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study

Thumbnail

D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study

Thumbnail

D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives

Thumbnail

D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus

Thumbnail

D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy

Thumbnail

D3.20 - Searching for an Alternative Contrast Agent in a Patient Allergic to Multiple Nonionic Iodinated Contrast Media

Thumbnail

D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania

Thumbnail

D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts